论文部分内容阅读
目的观察贝那普利联合来氟米特治疗IgA肾病的临床疗效。方法 60例IgA肾病患者随机分为两组:治疗组30例,给予贝那普利10mg/d联合来氟米特20mg/d;对照组30例,单用贝那普利10mg/d。疗程均为6个月。比较两组临床疗效。结果治疗组总有效率为83.3%(25/30),明显高于对照组的66.7%(20/30)(P<0.05)。治疗组治疗后尿蛋白定量为(0.62±0.24)g/24h,低于对照组的(1.62±0.46)g/24h,血清白蛋白为(40.36±10.32)g/L,高于对照组的(32.86±10.31)g/L(P<0.05)。结论贝那普利联合来氟米特治疗IgA肾病能提高患者血清白蛋白水平,减少蛋白尿。
Objective To observe the clinical efficacy of benazepril combined with leflunomide in the treatment of IgA nephropathy. Methods Sixty patients with IgA nephropathy were randomly divided into two groups: treatment group 30 cases, benazepril 10 mg / d combined with leflunomide 20 mg / d; control group 30 cases, benazepril 10 mg / d alone. Course of treatment are 6 months. The clinical efficacy of the two groups were compared. Results The total effective rate in the treatment group was 83.3% (25/30), which was significantly higher than that in the control group (66.7%, 20/30) (P <0.05). Urinary protein in the treatment group after treatment was (0.62 ± 0.24) g / 24h, lower than that in the control group (1.62 ± 0.46) g / 24h and serum albumin (40.36 ± 10.32) g / L, 32.86 ± 10.31) g / L (P <0.05). Conclusion The combination of benazepril and leflunomide in the treatment of IgA nephropathy can improve serum albumin and reduce proteinuria in patients.